A Single-center, Open-label, Three-period, Fixed-sequence Design Study to Investigate the Effect of Daridorexant on the Pharmacokinetics of Dabigatran and Rosuvastatin in Healthy Male Subjects
Latest Information Update: 10 Nov 2022
At a glance
- Drugs Dabigatran etexilate (Primary) ; Daridorexant (Primary) ; Rosuvastatin (Primary)
- Indications Insomnia; Sleep apnoea syndrome
- Focus Pharmacokinetics
- Sponsors Idorsia Pharmaceuticals
Most Recent Events
- 07 Nov 2022 Status changed from recruiting to completed.
- 20 Oct 2022 Planned End Date changed from 30 Sep 2022 to 30 Oct 2022.
- 20 Oct 2022 Planned primary completion date changed from 30 Sep 2022 to 30 Oct 2022.